Low Dose Radiation Therapy for Glioblastoma Multiforme
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and effectiveness of low dose rate radiation therapy plus
temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic
Astrocytoma or Glioblastoma Multiforme) who have previously been treated with surgery
followed by radiation surgical resection followed by adjuvant radiation therapy plus
temozolomide.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins